spacer
home > ebr > winter 2018 > particle acceleration
PUBLICATIONS
European Biopharmaceutical Review

Particle Acceleration

First established more than 200 years ago as a defence against infectious diseases, vaccine development proliferated in the mid-20th century as researchers began to fully exploit the use of inactive and attenuated disease strains. The key to a successful vaccine is to identify and isolate an agent that can be safely administered to the patient to trigger a sufficiently protective immune response, without causing a full-blown illness. For some diseases, a completely inactive strain performs this function, while for others attenuation or modification of an active strain – often by passaging through animal embryos – provides an answer.

More recently, newer vaccine technologies have been adopted to tackle diseases not amenable to these traditional approaches. Today’s researchers routinely deploy subunit and conjugate vaccines – both of which contain only fractions of the pathogen for which they provide protection – and viruslike particles (VLPs). These ‘trick’ the body into an immune response by precisely mimicking the morphology and outer surface of the live virus, but lack the genetic material needed to reproduce, thereby offering the same levels of safety as inactive vaccines. In vivo, such VLPs must be effectively indistinguishable from the active pathogen, so their structure is critical.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Dave Stuart is Medical Research Council Professor of structural biology at the University of Oxford, UK, and joint-head of the division of structural biology at the Department of Clinical Medicine. He was appointed Director of Life Sciences at Diamond Light Source in 2008. Dave’s principal research interests include the structure of viruses and viral proteins, as well as cellular proteins, especially those that interact with viruses.
spacer
Diamond Light Source
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Acquires UK-based Clinical Trials Laboratory Services

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also offers full-service cell processing capabilities on site.
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 
Industry Events

PDA Parenteral Packaging 2019

19-20 March 2019, Hilton Molino Stucky, Venice, Italy

PDA Europe’s Conference has become a must-attend event for all professionals in the Parenteral Packaging arena. Join us in Venice in March 2019 to continue and further deepen scientific advancements and our ongoing professional discourse of latest on primary packaging technologies and business trends. This conference and the accompanying exhibition address quality of components and cont­ainers, container closure development and integrity testing as well as aspects of processing, product distribution and storage.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement